|Bid||6.66 x 4000|
|Ask||6.66 x 1200|
|Day's range||6.22 - 6.66|
|52-week range||5.39 - 18.73|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up 11% Monday afternoon after the late-stage biotech company announced on Friday that it had filed a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for its therapy Lifileucel. The drug is the company's lead pipeline candidate, and the BLA is seeking approval for the drug to treat patients with advanced unresectable or metastatic melanoma who have already had a PD-1/L1 therapy (a checkpoint inhibitor anticancer drug that blocks the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells). The company, which focuses on novel T cell-based cancer immunotherapies, is using the company's phase 2 trial of the drug that dosed post-anti-PD1 melanoma patients with Lifileucel.
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.